While in general AD is most commonly multifactorial and difficult to tackle therapeutically, these findings suggest that especially female APOE4 carriers with AD could benefit from targeting these neutrophil-microglia interactions, specifically the IL-17F/IL-17RA axis, possibly in combinatorial therapeutic approaches to reduce cognitive decline. Here, IL17RA is linked to Alzheimer disease.